Opinion|Videos|November 19, 2026

Clinical Scenario: CELMoD Selection Before CAR T-Cell Therapy in Multiple Myeloma

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss a clinical scenario involving a 63-year-old patient with multiple myeloma who relapsed after frontline quadruplet therapy, autologous stem cell transplantation, lenalidomide maintenance, and subsequent carfilzomib-based treatment.

In this segment, Dr. Joseph Mikhael and Dr. Scott Goldsmith discuss a clinical scenario involving a 63-year-old patient with multiple myeloma who relapsed after frontline quadruplet therapy, autologous stem cell transplantation, lenalidomide maintenance, and subsequent carfilzomib-based treatment. With the patient remaining sensitive to CD38-targeted therapy and preparing for CAR T-cell therapy, Dr. Goldsmith considers daratumumab plus iberdomide as a potential holding and bridging strategy to control disease burden. He discusses the rationale for using the same regimen across both phases, including the potential to support T-cell function and avoid compromising CAR T-cell manufacturing. The experts also discuss concerns about using bispecific antibodies before T-cell collection because of their potential to contribute to T-cell exhaustion or impair manufacturing. Dr. Mikhael highlights iberdomide's tolerability profile as another potential advantage. The discussion emphasizes individualized treatment selection and the need for further evidence to establish the effects of CELMoDs on CAR T-cell manufacturing and outcomes in multiple myeloma.


Related to this article